Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Salmonella Typhi Vi capsular polysaccharide-specific B cell receptor (BCR) is a membrane-bound immunoglobulin complex expressed on the surface of specific B lymphocytes. It plays a critical role in the adaptive immune recognition of Salmonella enterica serovar Typhi, the causative agent of typhoid fever. The Vi capsular polysaccharide is a major virulence factor of S. Typhi that shields the bacterium from complement deposition and phagocytosis. When vaccines containing the Vi antigen (either as a plain polysaccharide or conjugated to a carrier protein) are administered, they target these specific BCRs. Binding and cross-linking of the BCRs by the Vi antigen activate intracellular signaling cascades, leading to B cell proliferation, clonal expansion, and the production of protective anti-Vi antibodies.
Vaccine antigens bind to and cross-link Vi capsular polysaccharide-specific B cell receptors on B lymphocytes, triggering receptor-mediated signaling, clonal expansion, and differentiation into antibody-secreting plasma cells and memory B cells to provide protective immunity against Salmonella Typhi.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Salmonella Typhi Vi capsular polysaccharide-specific B cell receptor (Vi-specific BCR).